Olfactive Biosolutions to Present at FoodTech World Cup Conference Final on May 15
Olfactive Biosolutions, a trailblazing biotechnology company specializing in the adaptation of food molecules to treat chronic diseases, has secured a spot as a finalist in the highly esteemed FoodTech World Cup. This international event will take place in Lausanne, Switzerland, on May 15, 2025, and brings together the most innovative startups shaping the future of nutrition and health.
Backed by industry titans Givaudan and Nestlé Research and Development Lausanne, the FoodTech World Cup is widely recognized as one of the most competitive and influential global showcases in the food innovation space. This unique platform not only celebrates groundbreaking ideas but also seeks to identify the next generation of startups capable of addressing one of the most urgent challenges of our time: transforming food into a powerful tool for managing and preventing chronic diseases such as obesity, diabetes, and hypertension.
Representing Olfactive Biosolutions at the event will be Co-founder and Chief Technology Officer Chris Hanson, who is scheduled to speak at the conference and present the company’s revolutionary technology to an international audience of researchers, investors, entrepreneurs, and food industry leaders. Deborah Stapleton, Vice President of Media Relations for Olfactive Biosolutions, will also be in attendance to engage with media outlets and strategic partners.
At the heart of Olfactive Biosolutions’ innovation is Pivit™, the company’s proprietary, all-natural formulation designed to trigger the body’s natural satiety pathways. When taken as a daily supplement or incorporated into food and beverage products, Pivit™ stimulates the simultaneous secretion of three key hormones—GLP-1 (glucagon-like peptide-1), PYY (peptide YY), and GIP (gastric inhibitory polypeptide). These hormones play a critical role in regulating appetite, insulin sensitivity, and blood sugar levels.
Unlike pharmaceutical interventions that rely on synthetic compounds and can come with unwanted side effects or high costs, Olfactive Biosolutions is harnessing naturally occurring compounds found in everyday foods. Using its advanced sensory biochemistry platform, the company has identified specific food molecules that activate receptors in the gut responsible for the production of GLP-1 and other mediators involved in feelings of fullness and metabolic regulation. This novel approach places the company at the forefront of a new era in nutritional science—where food becomes precision-targeted therapy.
“The science behind Pivit™ is incredibly exciting,” explained Hanson. “By identifying which foods trigger specific gut hormone responses, we’ve developed a solution that not only helps individuals lose weight but does so in a way that aligns with how the body naturally regulates appetite and metabolism. It’s a fundamentally different approach to chronic disease management—one that is safer, more affordable, and scalable across populations.”
The potential public health implications of this innovation are vast. Obesity and type 2 diabetes remain among the leading causes of preventable death worldwide, contributing to cardiovascular disease, kidney failure, and reduced quality of life. Many individuals face barriers to accessing effective treatments, whether due to cost, side effects, or lack of efficacy. By offering a natural and accessible alternative, Olfactive Biosolutions aims to democratize health and wellness.
“Our mission is to make metabolic health accessible to everyone,” Hanson continued. “We believe that food—when properly understood at a molecular level—can be one of the most powerful therapeutic tools we have. With Pivit™, we’re turning ordinary food ingredients into extraordinary health solutions.”
To date, Olfactive Biosolutions has been granted six U.S. patents specifically focused on the treatment of obesity, type 2 diabetes, and hypertension using food-based molecular formulations. Additionally, the company has filed 12 more patents covering a broader range of chronic conditions. This robust intellectual property portfolio not only protects the company’s pioneering work but also positions it as a long-term leader in the functional nutrition and nutraceutical sectors.
Looking ahead, the company is preparing for the commercial launch of Pivit™ as an over-the-counter daily supplement. Consumers will be able to purchase the product directly through the company’s website beginning in September 2025. In parallel, Olfactive Biosolutions is actively pursuing strategic partnerships with multinational food and beverage companies to develop a range of consumer products—such as snack bars, beverages, and ready-to-eat meals—enhanced with the Pivit™ formulation.
“Our pipeline includes several co-branded products in development,” said Stapleton. “These collaborations will allow consumers to experience the benefits of Pivit™ in familiar formats—like a morning smoothie or an afternoon snack—integrating seamlessly into their daily routines while supporting long-term health goals.”
The company’s selection as a finalist in the FoodTech World Cup follows its recent win in the North American regional competition, where it was chosen from a pool of more than 100 startups spanning 20 countries. Only ten companies advanced to the global finals in Lausanne, underscoring the rigor of the selection process and the exceptional caliber of Olfactive Biosolutions’ science and vision.
“We are honored to represent North America at the FoodTech World Cup and to share our work on a global stage,” said Hanson. “This is more than a competition—it’s an opportunity to accelerate the adoption of sustainable, health-promoting technologies and to spark new collaborations that could change millions of lives.”
As public interest in health-focused foods continues to surge and as regulatory agencies increase their scrutiny of ultra-processed, high-sugar products, Olfactive Biosolutions stands at the nexus of science, nutrition, and innovation. With a growing body of evidence supporting the efficacy of gut-hormone-based interventions, and with market trends favoring clean-label and functional ingredients, the timing for the company’s launch and expansion could not be more opportune.
In the coming months, Olfactive Biosolutions plans to expand its research team, deepen its clinical testing, and broaden consumer education efforts around the benefits of GLP-1 and related pathways. As the company takes the global stage in Lausanne, it signals the beginning of a new chapter—where science-backed nutrition takes center stage in the fight against chronic disease.
For more information on Pivit™ or to follow Olfactive Biosolutions’ journey,
